LSD – from counterculture to clinical trials

Billy Odell Tucker-Robinson Founder & Host — Banking With Billy Network • Intelligence Network • Data Science • AI Research • World News
Published: 2026-10-07T22:20:31.393Z • Permanent link

LSD, or lysergic acid diethylamide, has a long and storied history that spans from its origins as a psychedelic compound in the 1930s to its current status as a promising therapeutic agent in clinical trials. The story begins with Swiss chemist Albert Hofmann, who first synthesized LSD in 1938 at Sandoz Pharmaceuticals. Hofmann's discovery was initially met with skepticism, but he continued to study the compound, eventually determining its psychoactive properties in 1943.

Hofmann's work laid the groundwork for LSD's use in psychotherapy, particularly in the 1950s and 1960s, when it was used by prominent psychiatrists such as Timothy Leary and Stanislav Grof. However, as the counterculture movement of the 1960s gained momentum, LSD's reputation as a recreational substance became widespread, leading to its classification as a Schedule I controlled substance in the United States in 1970. Despite this classification, research into LSD's therapeutic potential has continued, with many scientists and researchers pushing for its reclassification and further study.

Today, a new wave of research into LSD is underway, with several institutions and companies working to develop the compound into a safe and effective treatment for a range of mental health conditions, including depression, anxiety, and PTSD. Companies such as Empower Mind and COMPASS Pathways are leading this charge, with several clinical trials already underway to test the efficacy and safety of LSD as a therapeutic agent.

LSD's re-emergence as a therapeutic agent has significant implications for the AI & Tech Ecosystems domain. Companies such as IBM and Microsoft are already leveraging AI and machine learning to analyze and interpret large datasets related to mental health, and LSD's potential as a treatment for mental health conditions could further accelerate this trend. Researchers at institutions such as the University of California, Los Angeles, are also exploring the use of AI and machine learning to predict patient outcomes and optimize treatment regimens.

The implications of LSD's re-emergence are not limited to the tech sector, however. Markets such as the biotech industry are likely to be heavily impacted, with companies such as Pfizer and Johnson & Johnson already investing heavily in research and development of new treatments for mental health conditions. Furthermore, policymakers and regulatory agencies, such as the FDA and the DEA, will need to re-examine their approach to LSD and other psychedelics, potentially leading to changes in the way these substances are classified and regulated.

LSD's re-emergence as a therapeutic agent is not an isolated phenomenon. Other psychedelics, such as psilocybin and DMT, are also being studied for their potential therapeutic benefits, and several institutions and companies are working to develop these compounds into safe and effective treatments. This trend is part of a broader shift towards the use of psychedelics in medicine, which is being driven in part by advances in neuroscience and the development of new technologies, such as functional magnetic resonance imaging (fMRI).